Literature DB >> 16188969

Distinct functional sites for human immunodeficiency virus type 1 and stromal cell-derived factor 1alpha on CXCR4 transmembrane helical domains.

Shaomin Tian1, Won-Tak Choi, Dongxiang Liu, James Pesavento, Youli Wang, Jing An, Joseph G Sodroski, Ziwei Huang.   

Abstract

The entry of human immunodeficiency virus type 1 (HIV-1) into the cell is initiated by the interaction of the viral surface envelope protein with two cell surface components of the target cell, CD4 and a chemokine coreceptor, usually CXCR4 or CCR5. The natural ligand of CXCR4 is stromal cell-derived factor 1alpha (SDF-1alpha). Whereas the overlap between HIV-1 and SDF-1alpha functional sites on the extracellular domains of CXCR4 has been well documented, it has yet to be determined whether there are sites in the transmembrane (TM) helices of CXCR4 important for HIV-1 and/or SDF-1alpha functions, and if such sites do exist, whether they are overlapping or distinctive for the separate functions of CXCR4. For this study, by employing alanine-scanning mutagenesis, (125)I-SDF-1alpha competition binding, Ca(2+) mobilization, and cell-cell fusion assays, we found that the mutation of many CXCR4 TM residues, including Tyr(45), His(79), Asp(97), Pro(163), Trp(252), Tyr(255), Asp(262), Glu(288), His(294), and Asn(298), could selectively decrease HIV-1-mediated cell fusion but not the binding activity of SDF-1alpha. Phe(87) and Phe(292), which were involved in SDF-1alpha binding, did not play a significant role in the coreceptor activity of CXCR4, further demonstrating the disconnection between physiological and pathological activities of CXCR4 TM domains. Our data also show that four mutations of the second extracellular loop, D182A, D187A, F189A, and P191A, could reduce HIV-1 entry without impairing either ligand binding or signaling. Taken together, our first detailed characterization of the different functional roles of CXCR4 TM domains may suggest a mechanistic basis for the discovery of new selective anti-HIV agents.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16188969      PMCID: PMC1235829          DOI: 10.1128/JVI.79.20.12667-12673.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  34 in total

1.  The core domain of chemokines binds CCR5 extracellular domains while their amino terminus interacts with the transmembrane helix bundle.

Authors:  Cédric Blanpain; Benjamin J Doranz; Antoine Bondue; Cédric Govaerts; Anne De Leener; Gilbert Vassart; Robert W Doms; Amanda Proudfoot; Marc Parmentier
Journal:  J Biol Chem       Date:  2002-12-03       Impact factor: 5.157

2.  Identification of allosteric peptide agonists of CXCR4.

Authors:  Aristidis Sachpatzidis; Benjamin K Benton; John P Manfredi; Hua Wang; Andrew Hamilton; Henrik G Dohlman; Elias Lolis
Journal:  J Biol Chem       Date:  2002-11-03       Impact factor: 5.157

3.  Structural and functional characterization of human CXCR4 as a chemokine receptor and HIV-1 co-receptor by mutagenesis and molecular modeling studies.

Authors:  N Zhou; Z Luo; J Luo; D Liu; J W Hall; R J Pomerantz; Z Huang
Journal:  J Biol Chem       Date:  2001-09-10       Impact factor: 5.157

Review 4.  The molecular biology of leukocyte chemoattractant receptors.

Authors:  P M Murphy
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

Review 5.  Structure and function of G protein-coupled receptors.

Authors:  C D Strader; T M Fong; M R Tota; D Underwood; R A Dixon
Journal:  Annu Rev Biochem       Date:  1994       Impact factor: 23.643

6.  A new generation of Ca2+ indicators with greatly improved fluorescence properties.

Authors:  G Grynkiewicz; M Poenie; R Y Tsien
Journal:  J Biol Chem       Date:  1985-03-25       Impact factor: 5.157

7.  Identification of CXCR4 domains that support coreceptor and chemokine receptor functions.

Authors:  B J Doranz; M J Orsini; J D Turner; T L Hoffman; J F Berson; J A Hoxie; S C Peiper; L F Brass; R W Doms
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

8.  Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex.

Authors:  C Wild; J W Dubay; T Greenwell; T Baird; T G Oas; C McDanal; E Hunter; T Matthews
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

9.  Fusogenic mechanisms of enveloped-virus glycoproteins analyzed by a novel recombinant vaccinia virus-based assay quantitating cell fusion-dependent reporter gene activation.

Authors:  O Nussbaum; C C Broder; E A Berger
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

10.  Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.

Authors:  C T Wild; D C Shugars; T K Greenwell; C B McDanal; T J Matthews
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

View more
  35 in total

1.  Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists.

Authors:  Beili Wu; Ellen Y T Chien; Clifford D Mol; Gustavo Fenalti; Wei Liu; Vsevolod Katritch; Ruben Abagyan; Alexei Brooun; Peter Wells; F Christopher Bi; Damon J Hamel; Peter Kuhn; Tracy M Handel; Vadim Cherezov; Raymond C Stevens
Journal:  Science       Date:  2010-10-07       Impact factor: 47.728

Review 2.  Drug discovery research targeting the CXC chemokine receptor 4 (CXCR4).

Authors:  Won-Tak Choi; Srinivas Duggineni; Yan Xu; Ziwei Huang; Jing An
Journal:  J Med Chem       Date:  2011-12-02       Impact factor: 7.446

3.  Critical role in CXCR4 signaling and internalization of the polypeptide main chain in the amino terminus of SDF-1α probed by novel N-methylated synthetically and modularly modified chemokine analogues.

Authors:  Chang-Zhi Dong; Shaomin Tian; Won-Tak Choi; Santhosh Kumar; Dongxiang Liu; Yan Xu; Xiaofeng Han; Ziwei Huang; Jing An
Journal:  Biochemistry       Date:  2012-07-23       Impact factor: 3.162

4.  Dual targeting of the chemokine receptors CXCR4 and ACKR3 with novel engineered chemokines.

Authors:  Melinda S Hanes; Catherina L Salanga; Arnab B Chowdry; Iain Comerford; Shaun R McColl; Irina Kufareva; Tracy M Handel
Journal:  J Biol Chem       Date:  2015-07-27       Impact factor: 5.157

Review 5.  Targeting chemokine receptor CXCR4 for treatment of HIV-1 infection, tumor progression, and metastasis.

Authors:  Won-Tak Choi; Yilei Yang; Yan Xu; Jing An
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

6.  Molecular recognition of CXCR4 by a dual tropic HIV-1 gp120 V3 loop.

Authors:  Phanourios Tamamis; Christodoulos A Floudas
Journal:  Biophys J       Date:  2013-09-17       Impact factor: 4.033

7.  A novel synthetic bivalent ligand to probe chemokine receptor CXCR4 dimerization and inhibit HIV-1 entry.

Authors:  Won-Tak Choi; Santhosh Kumar; Navid Madani; Xiaofeng Han; Shaomin Tian; Chang-Zhi Dong; Dongxiang Liu; Srinivas Duggineni; Jian Yuan; Joseph G Sodroski; Ziwei Huang; Jing An
Journal:  Biochemistry       Date:  2012-08-29       Impact factor: 3.162

8.  Unique ligand binding sites on CXCR4 probed by a chemical biology approach: implications for the design of selective human immunodeficiency virus type 1 inhibitors.

Authors:  Won-Tak Choi; Shaomin Tian; Chang-Zhi Dong; Santosh Kumar; Dongxiang Liu; Navid Madani; Jing An; Joseph G Sodroski; Ziwei Huang
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

Review 9.  Lifting the lid on GPCRs: the role of extracellular loops.

Authors:  M Wheatley; D Wootten; M T Conner; J Simms; R Kendrick; R T Logan; D R Poyner; J Barwell
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

10.  Computer-based design of novel HIV-1 entry inhibitors: neomycin conjugated to arginine peptides at two specific sites.

Authors:  Alexander Berchanski; Aviva Lapidot
Journal:  J Mol Model       Date:  2008-12-05       Impact factor: 1.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.